Immunomedics Inc. said that its colorectal cancer imagingagent, ImmuRAID-CEA, has induced virtually no immunogenicresponse or human anti-mouse antibody (HAMA) response inmore than 200 patients given a single injection.

The Morris Plains, N.J., company (NASDAQ:IMMU) has appliedfor FDA approval to market ImmuRAID-CEA for colorectalcancer and has also sought Committee for ProprietaryMedicinal Products approval in Europe.

Most other products that employ an intact antibody haveinduced a HAMA response in 30 percent to 40 percent ofpatients after a single injection, Hans Hansen, vice president ofexploratory research told the meeting of the Society of NuclearMedicine in Los Angeles. The occurrence of HAMA maypreclude the administration of additional antibody-basedimaging or therapy products, he said.

(c) 1997 American Health Consultants. All rights reserved.